Strata Critical Medical (SRTA) has reported its FY 2025 numbers, with Q4 revenue at US$66.8 million and a basic EPS loss of US$0.06. Trailing twelve month revenue came in at US$197.1 million with a full year basic EPS loss of US$0.24. Over recent quarters, the company has reported revenue in a range from US$36.1 million to US$66.8 million, while quarterly basic EPS losses have moved between US$0.04 and US$0.12. This keeps the focus on how efficiently it is converting sales into earnings. With the shares trading around US$4.89, this update centers on whether margins can move in the right direction from here and support the ongoing investment case.

See our full analysis for Strata Critical Medical.

With the headline figures reported, the next step is to see how these results compare with the stories investors already tell about Strata Critical Medical and where the data may challenge those narratives.

Losses Still Material At US$20.1 Million Over The Year

• On a trailing twelve month basis, Strata Critical Medical recorded a net income loss of US$20.1 million on US$197.1 million of revenue, with basic EPS at a loss of US$0.24.
• Consensus narrative points to medical transport as a solid foundation for long term earnings potential, yet the trailing loss and EPS trends create a gap between that story and the current numbers.
  • The business has been unprofitable over the last 12 months and losses have worsened over the past five years at about 7.6% per year, which sits awkwardly against ideas of resilient and predictable earnings.
  • Q4 FY 2025 net income from continuing operations was a loss of US$5.4 million, similar to prior loss levels like the US$9.8 million loss in Q4 FY 2024, so any long term margin expansion story still has to contend with these ongoing red figures.

Premium 2.2x P/S Multiple Versus Healthcare Peers

• The shares trade on a P/S of 2.2x compared with a peer average of 1.0x and a US Healthcare industry average of 1.3x, while the stock price sits around US$4.89.
• Bulls argue that medical air mobility and M&A can justify a higher multiple, but the current valuation sits on top of loss making financials.
  • The bullish narrative leans on future revenue scale and margin expansion, yet trailing results show a loss of US$20.1 million and no positive EPS in any of the reported quarters.
  • With no DCF fair value available from the data and no profitability in the last year, the 2.2x P/S premium rests on expectations rather than on cash generation or earnings today.

Have a look at how optimistic investors frame that upside case and decide whether the current 2.2x P/S multiple feels justified for you personally. 🐂 Strata Critical Medical Bull Case

Short Cash Runway Adds Pressure To Widening Loss Trend

• Trailing data highlights a cash runway of less than one year alongside multi year earnings declines of about 7.6% annually, which makes the recent US$20.1 million loss more important for equity holders.
• Bears focus on this tight liquidity and loss pattern as key risks that could weigh heavily on shareholders if conditions do not improve.
  • The company has been loss making across all listed quarters, with basic EPS losses between US$0.04 and US$0.12 per quarter, so there is no recent period in the data where profits offset cash usage.
  • With no rewards flagged in the trailing risk summary and a short runway, critics see limited room for missteps while the business trades at a premium 2.2x P/S multiple.

If you are weighing those downside arguments, it can help to see the full cautionary case set out in one place before you make up your mind. 🐻 Strata Critical Medical Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Strata Critical Medical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this all feels mixed, that is the point, and it is why acting promptly to check the underlying data for yourself really matters. To see what the numbers are flagging in terms of potential concerns, take a closer look at the 2 important warning signs and weigh those against your own view.

Explore Alternatives

Strata Critical Medical carries ongoing losses, a short cash runway and a premium 2.2x P/S multiple, which together raise questions about resilience and downside risk.

If that mix of widening losses and tight liquidity makes you cautious, take a few minutes to check out 77 resilient stocks with low risk scores that prioritise steadier financial profiles and potentially lower volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.